Preoperative elevation of serum C-reactive protein is predictive for prognosis in myeloma bone disease after surgery

British Journal of Cancer

Volumn 95, Issue 7, 2006, Pages 782-787

  Zahlten Hinguranage, A ^a   Goldschmidt, H ^a   Cremer, F W ^a   Egerer, G ^a   Moehler, T ^a   Witte, D ^a   Bernd, L ^a   Sabo, D ^a   Zeifang, F ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bone; CRP; Multiple myeloma; Prognostic factor; Surgery

Indexed keywords

C REACTIVE PROTEIN; LACTATE DEHYDROGENASE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BONE DISEASE; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTIVARIATE ANALYSIS; MYELOMA; OSTEOLYSIS; OVERALL SURVIVAL; PATHOLOGY; PATIENT ASSESSMENT; PREDICTION; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL TECHNIQUE; WEIGHT BEARING;

ADULT; AGED; C-REACTIVE PROTEIN; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; ORTHOPEDIC PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749334968     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603329     Document Type: Article

References (33)

1. Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS (2003) Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 72: 229-233
2. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733-737
3. Berenson JR (2005) Myeloma bone disease. Best Pract Res Clin Haematol 18: 653-672
4. Biro L, Domjan G, Falus A, Jakab L, Cseh K, Kalabay L, Tarkovacs G, Tresch J, Malless E, Kramer J, Prohaszka Z, Jako J, Füst G, Csaszar A (1998) Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 28: 679-686
5. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoror M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gaharton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Okel M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol 4: 379-398
6. Frankel HL (1969) Ascending cord lesion in the early stages following spinal injuries. Paraplegia 7: 111-118
7. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmid-Wolf I, Gorschluter M (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584-593
8. Goldschmidt H, HD-2 Studie der German-Speaking Myeloma Multicenter Group (GMMG) (2003) Einmalige vs zweimalige Hochdosistherapie de Multiplen Myelomas. Deutsche Krebshilfe (Eds). Forum DGK1
9. Hannisdal E, Kildahl-Andersen O, Grottum KA, Lamvik J (1990) Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol 45: 198-202
10. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K (2005) The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864. DOI: 10.1002/cncr.20976
11. Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto M, Chizuka R, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A (2002) Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Ann Hematol 81: 33-36
12. Kurzrock R (1997) Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res 3: 2581-2584
13. Kyriakou D, Papadaki H, Eliopoulos AG, Foudoulakis A, Alexandrakis M, Eliopoulos GD (1997) Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int J Hematol 66: 367-371
14. Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452
15. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31: 351-357
16. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H (1991) Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77: 2794-2795
17. Mirels H (1989) Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 249: 256-264
18. Morgan GJ, Davies FE (2005) Evolving treatment strategies for myeloma. Br J Cancer 92: 217-221
19. Nachbaur DM, Herold M, Maneschg A, Huber H (1991) Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 2: 54-58
20. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H (2002) Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 99: 167-170
21. Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335-338
22. Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD (1997) Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 97: 191-195
23. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85: 765-771
24. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1996) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 92: 370-374
25. Rajkumar SV, Kyle RA (2005) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80: 1371-1382
26. San Miguel FJ, Fonseca R, Greipp PR (2004) Prognostic factors and classification for multiple myeloma (contribution to clinical management). In Malpas JS (ed) Myeloma, Biology and Management. Philadelphia: Saunders, p 189ff
27. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83: 248-252
28. Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A (1998) The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 82: 1860-1866
29. Terpos ER, Szydlo JF, Apperley E, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman J, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069
30. Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi TT (1994) Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 86: 391-393
31. Tricot G, Barlogie B, van Rhee F (2004) Treatment advances in multiple myeloma. Haemataol 25: 24-30
32. Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M (1998) Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 100: 129-134
33. Zeifang F, Zahlten-Hinguranage A, Goldschmidt H, Cremer F, Bernd L, Sabo D (2005) Long-term survival after surgical intervention for bone disease in multiple myeloma. Ann Oncol 16: 222-227, DOI:10.1093/annoc/mdi054